Loading…
Develops oral small-molecule drugs targeting G protein-coupled receptors using a proprietary structural platform.
Develops oral small-molecule drugs targeting G protein-coupled receptors using a proprietary structural platform.
Has no approved drug; income is upfront and milestone payments from pharma partners such as Otsuka, plus money raised from investors. Its platform keeps receptor proteins in their working shape outside living cells so they can be studied and screened, and partners pay to use it on their chosen targets.
Moat: narrow (IP / patents, process know-how). Proprietary native GPCR structural platform enables drugging previously undruggable receptor targets.
Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 130
Size Septerna (SEPN) is a United States Health Care company (Biotechnology) with a market value of $2.28B, the 1714th largest of 3,117 United States companies the cockpit tracks. Shares closed at $48.85 on 6 Nov 2026.
Performance Over six months the shares gained 104.7%, against +7.0% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 13,520.1% over the last twelve months (peer median +4.1%); the operating margin is -56.7% (peer median -3.9%).
Valuation It trades at 19.5× enterprise value to sales against a peer median of 5.5× (3rd most expensive of 12).
Capital Return on invested capital runs 135.6 points below its cost of capital (15.7% WACC).
Short interest Short interest is 7.5% of the free float (15 Oct 2026).
Next results Next results expected around 25 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $98.9M | $46.0M | $1.07M | $151,000 | $0 |
| Revenue growth | — | +4,175% | +612% | — | — |
| Gross profit | $97.2M | $44.3M | -$326,000 | -$697,000 | -$577,000 |
| EBITDA | -$54.4M | -$79.2M | -$79.4M | -$44.7M | -$27.4M |
| Net income | -$24.2M | -$48.9M | -$71.8M | $567,000 | -$27.7M |
| Free cash flow | $105M | $110M | -$69.6M | -$41.6M | -$24.6M |
| Capital expenditure | $910,000 | $518,000 | $2.10M | $2.88M | $1.29M |
| Total debt | $22.5M | $23.6M | $25.5M | $12.6M | $710,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Septerna SEPN | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | $1.45B | -48% | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | $416M | -31% | +125% | -12% | 1.3× | n/a |
| Crinetics Pharmaceuticals CRNX | n/a | +109% | n/a | n/a | n/a | n/a |
| Viking Therapeutics VKTX | $3.42B | -17% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SEPN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +32.4% | +1.3% | 4th highest of 21 |
| 6-month return | +104.7% | +7.0% | 2nd highest of 21 |
| Distance from 52-week high | -4.4% | -28.5% | 6th highest of 21 |
| Revenue growth (TTM) | +13,520.1% | +4.1% | highest of 15 |
| Operating margin | -56.7% | -3.9% | 5th lowest of 13 |
| EV / Sales | 19.5× | 5.5× | 3rd most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 18.7% | 18.9% | 3rd least demanding of 5 |
| ROIC minus cost of capital | -135.6 pp | -6.4 pp | lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |